Literature DB >> 23462915

Risk assessment of upper tract urothelial carcinoma related to aristolochic acid.

Felicia Wu1, Tianxiu Wang.   

Abstract

BACKGROUND: Aristolochic acid is a toxin found in plants of the genus Aristolochia, to which humans can be exposed either through certain Chinese herbal medicines or through inadvertent commingling with food crops. Our objective was to estimate cumulative exposures of aristolochic acid associated with increased risk of end-stage renal disease (ESRD), and to conduct a systematic review and meta-analysis on aristolochic acid-induced upper tract urothelial carcinoma (UUC).
METHODS: Using epidemiologic studies on aristolochic acid-related disease from multiple different regions of the world, a systematic review was conducted in which relative risks (RR), HRs, and ORs were derived or extracted directly, and a meta-analysis was conducted. One study was used to estimate a benchmark dose lower confidence limit (BMDL) for aristolochic acid-related ESRD.
RESULTS: Mean values for risk ratios, ORs, RRs, or HRs, of UUC caused by aristolochic acid ranged from 1 to 49. A meta-analysis of these studies resulted in a pooled OR of 5.97 [95% confidence interval (CI), 2.78-12.84] for this aristolochic acid-related cancer. The obtained BMDL for aristolochic acid-related ESRD was 0.42 g cumulative aristolochic acid exposure.
CONCLUSIONS: Aristolochic acid exposure is significantly associated with an increased risk of UUC, and there is a dose-dependent relationship between cumulative aristolochic acid exposure and ESRD risk. IMPACT: Individuals who use certain Chinese herbal medicines may significantly increase their risk of developing UUC and/or ESRD, as would individuals who are inadvertently exposed to aristolochic acid through commingling of Aristolochia plants with harvested food crops.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462915      PMCID: PMC3650093          DOI: 10.1158/1055-9965.EPI-12-1386

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

1.  Some traditional herbal medicines, some mycotoxins, naphthalene and styrene.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2002

2.  Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Authors:  Bojan Jelaković; Sandra Karanović; Ivana Vuković-Lela; Frederick Miller; Karen L Edwards; Jovan Nikolić; Karla Tomić; Neda Slade; Branko Brdar; Robert J Turesky; Želimir Stipančić; Damir Dittrich; Arthur P Grollman; Kathleen G Dickman
Journal:  Kidney Int       Date:  2011-11-09       Impact factor: 10.612

3.  Final report on carcinogens background document for aristolochic acids.

Authors: 
Journal:  Rep Carcinog Backgr Doc       Date:  2008-09

4.  Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers.

Authors:  V Batuman
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

5.  Endemic nephropathy: the case for chronic poisoning by aristolochia.

Authors:  Tjasa Hranjec; Anamarija Kovac; Jelena Kos; Wenyang Mao; John J Chen; Arthur P Grollman; Bojan Jelaković
Journal:  Croat Med J       Date:  2005-02       Impact factor: 1.351

6.  Urothelial malignancy in nephropathy due to Chinese herbs.

Authors:  J P Cosyns; M Jadoul; J P Squifflet; P J Van Cangh; C van Ypersele de Strihou
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

7.  Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.

Authors:  Byeong Hwa Yun; Thomas A Rosenquist; Viktoriya Sidorenko; Charles R Iden; Chung-Hsin Chen; Yeong-Shiau Pu; Radha Bonala; Francis Johnson; Kathleen G Dickman; Arthur P Grollman; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2012-05-04       Impact factor: 3.739

8.  Aristolochic acid-associated urothelial cancer in Taiwan.

Authors:  Chung-Hsin Chen; Kathleen G Dickman; Masaaki Moriya; Jiri Zavadil; Viktoriya S Sidorenko; Karen L Edwards; Dmitri V Gnatenko; Lin Wu; Robert J Turesky; Xue-Ru Wu; Yeong-Shiau Pu; Arthur P Grollman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

9.  Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.

Authors:  J Xiao; X Zhu; G Y Hao; Y C Zhu; H J Hou; J Zhang; L L Ma; Y Tian; Y H Zhang
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

10.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

View more
  18 in total

1.  A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets.

Authors:  D E Marin; G C Pistol; M Gras; M Palade; I Taranu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-22       Impact factor: 3.000

2.  New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid.

Authors:  Byeong Hwa Yun; Viktoriya S Sidorenko; Thomas A Rosenquist; Kathleen G Dickman; Arthur P Grollman; Robert J Turesky
Journal:  Toxicol Res (Camb)       Date:  2015-07-01       Impact factor: 3.524

3.  Adenine versus guanine DNA adducts of aristolochic acids: role of the carcinogen-purine linkage in the differential global genomic repair propensity.

Authors:  Preetleen Kathuria; Purshotam Sharma; Stacey D Wetmore
Journal:  Nucleic Acids Res       Date:  2015-07-14       Impact factor: 16.971

Review 4.  Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?

Authors:  Pierre Colin; Thomas Seisen; Romain Mathieu; Sharohkh F Shariat; Morgan Rouprêt
Journal:  Transl Androl Urol       Date:  2016-10

5.  Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Wenlong Zhong; Lei Zhang; Jiajian Ma; Shan Shao; Rongcheng Lin; Xuesong Li; Gengyan Xiong; Dong Fang; Liqun Zhou
Journal:  Onco Targets Ther       Date:  2017-12-05       Impact factor: 4.147

Review 6.  Whole Medical Systems versus the System of Conventional Biomedicine: A Critical, Narrative Review of Similarities, Differences, and Factors That Promote the Integration Process.

Authors:  Erik W Baars; Harald J Hamre
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-13       Impact factor: 2.629

7.  Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.

Authors:  Hongli Shan; Wen Tian; Yazhao Hong; Bo Xu; Chunxi Wang; Bing Yu; Xiaoqing Wang
Journal:  BMC Complement Med Ther       Date:  2020-06-03

Review 8.  The Contribution of Complementary and Alternative Medicine to Reduce Antibiotic Use: A Narrative Review of Health Concepts, Prevention, and Treatment Strategies.

Authors:  Erik W Baars; Eefje Belt-van Zoen; Thomas Breitkreuz; David Martin; Harald Matthes; Tido von Schoen-Angerer; Georg Soldner; Jan Vagedes; Herman van Wietmarschen; Olga Patijn; Merlin Willcox; Paschen von Flotow; Michael Teut; Klaus von Ammon; Madan Thangavelu; Ursula Wolf; Josef Hummelsberger; Ton Nicolai; Philippe Hartemann; Henrik Szőke; Michael McIntyre; Esther T van der Werf; Roman Huber
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-03       Impact factor: 2.629

9.  Aristolochic Acid-Induced Genotoxicity and Toxicogenomic Changes in Rodents.

Authors:  Xi-Lin Li; Xiao-Qing Guo; Hai-Rong Wang; Tao Chen; Nan Mei
Journal:  World J Tradit Chin Med       Date:  2020-03-13

Review 10.  Interplay between chronic kidney disease (CKD) and upper tract urothelial carcinomas (UUC): foe or friend?

Authors:  Yehong Han; Dawei Shou; Liang Wen; Jianguang Shi; Jian Ding; Ping Gong; Weihua Gong
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.